Here are four quick facts.
1. The Boulder, Colo.-based company reported $8.75 million in revenues for the year, a $120,000 dip from fiscal year 2017.
2. In the fourth quarter of 2018, Encision posted a net loss of $18,000. It lost $115,000 the previous year.
3. Encision’s fourth quarter net revenue was $2.04 million.
4. Encision owns patented technology for preventing fatal stray electrosurgical burns during laparoscopic surgery.
“This past year has been a turning point for Encision,” President and CEO Greg Trudel said. “We delivered new levels of operational excellence, launched new products and delivered black ink on the bottom line for the first time in recent history. Our focus going forward will be to grow the top line. To that effect, we have already strengthened our sales channel with direct sales representation to fill strategic gaps in the marketplace and to eliminate underperforming distribution relationships.”
More articles on supply chain:
Medtronic appoints former J.P. Morgan Chase director to VP post — 5 highlights
Valeant no more — Valeant Pharmaceuticals rebranding as Bausch Health Companies
Integer to divest surgical, orthopedics product lines for $600M — 7 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.